Pramipexole

Overview

Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome. In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.[1] WP

Pramipexole was approved for medical use in the United States in 1997 and was first manufactured by Pharmacia and Upjohn. It is available as a generic medication. In 2023, it was the 201st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[1–5] WP

Drug class

Dopamine receptor agonist Dopamine D2-like receptor agonist Antiparkinsonian agent WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Pramipexole is used in the treatment of Parkinson's disease and restless legs syndrome. Safety in pregnancy and breastfeeding is unknown.[1][6] WP

A 2008 meta-analysis found that pramipexole was more effective than ropinirole in the treatment of restless legs syndrome.[7] WP

It is occasionally prescribed off-label for depression. Its effectiveness as an antidepressant may be a product of its strong partial agonistic activity on and preferential occupation of dopamine D₃ receptors at low doses (see table below); as well, the drug has been shown to desensitize the inhibitory D₂ autoreceptors but not the postsynaptic D₂ receptors, leading to an increase in dopamine and serotonin levels in the prefrontal cortex. Chronic administration of pramipexole may also result in desensitization of D₃ autoreceptors, leading to reduced dopamine transporter function. Trials have shown mixed results for depression.[8][9][10] WP

Pramipexole has also been used as a treatment for REM sleep behavior disorder, but it is not licensed for use in this disorder. Observational studies suggest it may reduce the frequency and intensity of REM sleep behavior disorder symptoms, but randomized controlled trials have not been performed, so the evidence for its role in this disorder is weak.[11] WP

Further parkinson's disease symptoms treatment

Parkinson's disease, apart from motor symptoms, is associated with chronic pain, which is mediated through three different mechanisms: nociception, neuropathy and nociplasty. In animal models, it was shown that pramipexole alleviates allodynia and hyperalgesia caused by excessive glial cell (astrocytes, microglia) activation in the spinal cord, which is the causative effect of Parkinson's disease-related nociceptive pain. Pramipexole appears to exert this effect through its anti-inflammatory effect by inhibiting the release of several pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-12 and IL-18). and NF-κB.[12–19] WP

Risks and side effects

Side effects

Common side effects of pramipexole include:[20][21][22] WP

• Headache[20][21][22] WP
• Peripheral edema[23] WP
• Hyperalgesia (body aches and pains)[20][21][22] WP
• Nausea and vomiting[20][21][22] WP
• Sedation and somnolence[20][21][22] WP
• Decreased appetite and subsequent weight loss[20][21][22] WP
• Orthostatic hypotension (resulting in dizziness, lightheadedness, and possibly fainting, especially when standing up)[20][21][22] WP
• Insomnia[20][21][22] WP
• Hallucinations (seeing, hearing, smelling, tasting or feeling things that are not there), amnesia and confusion[20][21][22] WP
• Twitching, twisting, or other unusual body movements[20][21][22] WP
• Unusual tiredness or weakness[20][21][22] WP
• Pramipexole (and related D₃-preferring dopamine agonist medications such as ropinirole) can induce "impulsive–compulsive spectrum disorders" such as compulsive gambling, punding, hypersexuality, and overeating, even in people without any prior history of these behaviors. There have also been reported detrimental side effects related to impulse-control disorders resulting from off-label use of pramipexole or other dopamine agonists in treating clinical depression. The incidence and severity of impulse-control disorders for those taking the drug for depression are not fully understood because the drug has not been approved for the treatment of depression and the first major studies of its efficacy in treating anhedonic depression were conducted in 2022. There have been anecdotal reports of abrupt and severe personality changes related to impulsivity and loss of self-control in a minority of patients regardless of the condition being treated, although the incidence of these side effects is not yet fully known.[24–28] WP
• Augmentation: Especially when used to treat restless legs syndrome, long-term pramipexole treatment may exhibit drug augmentation, which is "an iatrogenic worsening of [restless legs syndrome] symptoms following treatment with dopaminergic agents" and may include an earlier onset of symptoms during the day or a generalized increase in symptoms.[29][30][31] WP⚠ The source has a footnote here that is not shown.

Pharmacology

Pharmacology

The activity profile of pramipexole at various sites has been characterized as follows: WP⚠ A table follows this text in the source and is not copied here. Open the source to see it.

While pramipexole is used clinically (see below), its D₃-preferring receptor binding profile has made it a popular tool compound for preclinical research. For example, pramipexole has been used (in combination with D₂- and or D₃-preferring antagonists) to discover the role of D₃ receptor function in rodent models and tasks for neuropsychiatric disorders. Of note, it appears that pramipexole, in addition to having effects on dopamine D₃ receptors, may also affect mitochondrial function via a mechanism that remains less understood. A pharmacological approach to separate dopaminergic from non-dopaminergic (e.g. mitochondrial) effects of pramipexole has been to study the effects of the R-stereoisomer of pramipexole (which has much lower affinity to the dopamine receptors when compared to the S-isomer) side by side with the effects of the S-isomer. This property can be characterised using dopaminergic activity equivalent (a relative measure comparing doses of different doses of stereoisomers in mg).[32][33][34] WP

Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia. The substantia nigra has a high quantity of dopaminergic neurons, which are nerve cells that release the neurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia. When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer properly receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired. By acting as an agonist for the D₂, D₃, and D₄ dopamine receptors, pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia. WP⚠ Wikipedia itself has flagged this text: citation needed.

Pramipexole can increase growth hormone indirectly through its inhibition of somatostatin. Pramipexole has also been shown to be protective against dopaminergic-related methamphetamine neurotoxicity.[35][36][37] WP

Immediate-release pramipexole displays a Tₘₐₓ of approximately 2 hours and 3 hours if taken with a high-fat meal. Extended-release pramipexole displays a Tₘₐₓ of ~6 hours and ~8 hours if taken with food. The AUC of pramipexole remains unaltered regardless of food presence. Steady-state is achieved within 3 days and 5 days for the IR and ER formulations, respectively. Pramipexole is eliminated via the renal organic cation transporter as an unchanged drug showing no signs of any metabolism. Pramipexole has been shown to inhibit CYP2D6 with a Kᵢ of 30μM which is significantly higher than the maximum approved dosage of 4.5mg/day thus any enzyme-mediated drug interactions are not clinically relevant. It comes in strengths of 0.125mg, 0.25mg, 0.5mg, 1mg, and 1.5mg instant release; the extended-release comes in 0.375mg, 0.75mg, 1.5mg, 2.25mg, 3mg, 3.75mg, and 4.5mg. The instant release is meant to be dosed three times daily for Parkinson's and once two hours before bedtime for restless leg syndrome. The extended-release is not approved for restless leg syndrome. It is not metabolized, with >90% of the dose excreted unchanged via SCL22A2/OCT2. Therefore, inhibitors of the renal organic cation transporter system (e.g., cimetidine) will increase the area under the curve∞ by 50% and increase the t1/2 by 40%.[38][39] WP⚠ The source shows this formula as typeset maths. It is written out as plain text here.

Research

Cerebral ischemia and reperfusion injury

Pramipexole in combination with levodopa was shown to alleviate neurological repercussions, improve neuron morphology and their survival after cerebral ischemia-related reperfusion injury through ferroptosis inhibition (via Nrf2/GPX4/SLC7A11 pathway) or by mitochondrial membrane potential stabilization.[40][41] WP

Traumatic brain injury

After traumatic brain injury, neurons can undergo necroptosis via necrosome formation and RIPK1 pathway. Pramipexole was shown to act as a neuroprotective agent by inducing hypothermia.[42–45] WP

Psychiatry

Pramipexole has been evaluated for the treatment of sexual dysfunction experienced by some users of selective serotonin reuptake inhibitors. It has shown effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression, including neuroinflammatory subtypes via NLRP3 inflammasome pathway.[46–53] WP

Other indications

Pramipexole is under clinical trials for the treatment of fibromyalgia, essential tremor, primary orthostatic tremor ('shaky leg syndrome'), and persistent genital arousal disorder.[54–58] WP

Legal status

Brand names

Brand names include Mirapex, Mirapex ER, Mirapexin, Sifrol, Pexola, Pipexus, Glepark, Oprymea, Astepen, Calmolan, Erimexol, Ezaprev, Frodix, Galipeks, Labrixile, Mariprax, Medopexol, Mepimer, Minergi, Miparkan, Miraper, Miviren, Nulipar, Pacto, Panarak, Parim, Parixol, Parkipex, Parkyn, Parmital, Parpex, Pexa XR, Peximyr, Pexopar, Pisa, Portiv, Pradose, Pramigen, Pramipexin, Pramirol, Pramithon, Pranow, Prapex, Quera LP, Rampiex, Ramixole, Rapexole, Ritmorest, Axalanz, Biopsol, Derinik, Elderpat, Intaxel, Mirapapkin, Mirapezol, Movial, Muvend, Nervius, Neurosomat, Newmirex, Noxopran, Nulipar, Oxpola, Parmital, Periamid, Pralexan, Pramexol, Pramifer, Pramifrol, Pramiola, Pramip, Pramitrem, Primizol, Ramipex, Rapexole, Simipex, Simpral, Stabil, Treminel, Trimexol, X-Tremble.[59–63] WP

Chemistry

Formula

C10H17N3S PC

CAS number

104632-26-0 PC

Molar mass (g/mol)

211.33 PC

IUPAC name (computed by PubChem)

(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine PC

SMILES

CCCN[C@H]1CCC2=C(C1)SC(=N2)N PC

InChIKey

FASDKYOPVNHBLU-ZETCQYMHSA-N PC

PubChem CID

119570

IUPAC name

(S)-Nhair space6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Pramipexole Dihydrochloride Monograph for Professionals
2. Journal / agency Wilson SM, Wurst MG, Whatley MF, Daniels RN. Classics in Chemical Neuroscience: Pramipexole. ACS Chemical Neuroscience. 2020-09-02. doi:10.1021/acschemneuro.0c00332 · PMID 32786316
3. Other British national formulary: BNF 76. 2018
4. Other Top 300 of 2023
5. Other Pramipexole Drug Usage Statistics, United States, 2014 - 2023
6. Other Pramipexole Pregnancy and Breastfeeding Warnings
7. Journal / agency Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lleu PL, Finnern HW. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med. October 2008. doi:10.1016/j.sleep.2007.11.020 · PMID 18226947
8. Journal / agency Chernoloz O, El Mansari M, Blier P. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. Journal of Psychiatry & Neuroscience. February 2012. doi:10.1503/jpn.110038 · PMID 22023785 · PMC3297071
9. Journal / agency Castro-Hernández J, Afonso-Oramas D, Cruz-Muros I, Salas-Hernández J, Barroso-Chinea P, Moratalla R, Millan MJ, González-Hernández T. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake. Neurobiology of Disease. February 2015. doi:10.1016/j.nbd.2014.12.007 · PMID 25511804
10. Journal / agency Fawcett J, Rush AJ, Vukelich J, Diaz SH, Dunklee L, Romo P, Yarns BC, Escalona R. Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. The American Journal of Psychiatry. February 2016. doi:10.1176/appi.ajp.2015.15060788 · PMID 26844792
11. Journal / agency Tan SM, Wan YM. Pramipexole in the treatment of REM sleep behaviour disorder: A critical review. Psychiatry Res. 30 September 2016. doi:10.1016/j.psychres.2016.06.055 · PMID 27449005
12. Journal / agency Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, Beer S, Kesselring J, Stamelou M, Oertel WH, Möller JC, Lefaucheur JP. Pain in Parkinson's Disease: Current Concepts and a New Diagnostic Algorithm. Movement Disorders Clinical Practice. December 2015. doi:10.1002/mdc3.12217 · PMID 30363602 · PMC6178768
13. Journal / agency Mylius V, Perez Lloret S, Cury RG, Teixeira MJ, Barbosa VR, Barbosa ER, Moreira LI, Listik C, Fernandes AM, de Lacerda Veiga D, Barbour J, Hollenstein N, Oechsner M, Walch J, Brugger F, Hägele-Link S, Beer S, Rizos A, Chaudhuri KR, Bouhassira D, Lefaucheur JP, Timmermann L, Gonzenbach R, Kägi G, Möller JC, Ciampi de Andrade D. The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain. April 2021. doi:10.1097/j.pain.0000000000002107 · PMID 33044395 · PMC7977616
14. Journal / agency Godínez-Chaparro B, Rodríguez-Ramos MC, Martínez-Lorenzana MG, González-Morales E, Pérez-Ruíz KP, Espinosa de Los Monteros-Zuñiga A, Mendoza-Pérez F, Condes-Lara M. Pramipexole decreases allodynia and hyperalgesia via NF-κB in astrocytes in rats with Parkinson's disease. Pharmacology, Biochemistry, and Behavior. February 2025. doi:10.1016/j.pbb.2024.173945 · PMID 39675389
15. Journal / agency Chen Y, Li Y, Li C, Zhu D, Cheng O, Cui J. Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes. Neuroscience Letters. November 2022. doi:10.1016/j.neulet.2022.136933 · PMID 36283628
16. Journal / agency Rocha NP, Assis F, Scalzo PL, Vieira ÉL, Barbosa IG, de Souza MS, Christo PP, Reis HJ, Teixeira AL. Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson's Disease. Molecular Neurobiology. February 2018. doi:10.1007/s12035-017-0404-y · PMID 28176275
17. Journal / agency Lieberknecht V, Junqueira SC, Cunha MP, Barbosa TA, de Souza LF, Coelho IS, Santos AR, Rodrigues AL, Dafré AL, Dutra RC. Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice. Molecular Neurobiology. March 2017. doi:10.1007/s12035-016-9717-5 · PMID 26801190
18. Journal / agency Sanchez JE, Noor S, Sun MS, Zimmerly J, Pasmay A, Sanchez JJ, Vanderwall AG, Haynes MK, Sklar LA, Escalona PR, Milligan ED. The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1β and IL-10 expression from immune cell culture. Neuroscience Letters. September 2023. doi:10.1016/j.neulet.2023.137419 · PMID 37558176 · PMC10552878
19. Journal / agency Santamaria-Anzures J, Pérez-Ramos J, Mendoza-Pérez F, Godínez-Chaparro B. Pramipexole inhibits formalin-induce acute and long-lasting mechanical hypersensitivity via NF-kB pathway in rats. Drug Development Research. April 2023. doi:10.1002/ddr.22029 · PMID 36651647
20. Journal / agency MedlinePlus Drug Information: Pramipexole (Systemic)
21. Journal / agency Mirapex – pramipexole dihydrochloride tablet. 1 March 2020
22. Journal / agency Mirapex ER – pramipexole dihydrochloride tablet, extended release. 5 February 2020
23. Journal / agency Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Archives of Neurology. May 2000. doi:10.1001/archneur.57.5.729 · PMID 10815140
24. Journal / agency Napier TC, Kirby A, Persons AL. The role of dopamine pharmacotherapy and addiction-like behaviors in Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. August 2020. doi:10.1016/j.pnpbp.2020.109942 · PMID 32272129
25. Journal / agency Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clinic Proceedings. April 2009. doi:10.4065/84.4.310 · PMID 19339647 · PMC2665974
26. Journal / agency Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Internal Medicine. December 2014. doi:10.1001/jamainternmed.2014.5262 · PMID 25329919
27. Journal / agency Wolters EC, van der Werf YD, van den Heuvel OA. Parkinson's disease-related disorders in the impulsive-compulsive spectrum. Journal of Neurology. September 2008. doi:10.1007/s00415-008-5010-5 · PMID 18787882
28. Other Elliott C. The Degradation Drug
29. Journal / agency Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, Winkelman JW, Trenkwalder C, Sampaio C. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)^§. Movement Disorders. July 2018. doi:10.1002/mds.27260 · PMID 29756335
30. Other Pramipexole Monograph for Professionals
31. Journal / agency Salminen AV, Winkelmann J. Restless Legs Syndrome and Other Movement Disorders of Sleep-Treatment Update. Current Treatment Options in Neurology. November 2018. doi:10.1007/s11940-018-0540-3 · PMID 30411165
32. Journal / agency Weber M, Chang WL, Breier M, Ko D, Swerdlow NR. Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation. Behavioural Pharmacology. December 2008. doi:10.1097/FBP.0b013e32831c3b2b · PMID 19020413 · PMC3255557
33. Journal / agency Chang WL, Weber M, Breier MR, Saint Marie RL, Hines SR, Swerdlow NR. Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats. Brain Research. February 2012. doi:10.1016/j.brainres.2011.12.007 · PMID 22227455 · PMC3268831
34. Other Compositions and Methods of Using (R)-Pramipexole
35. Journal / agency Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. British Journal of Clinical Pharmacology. November 2007. doi:10.1111/j.1365-2125.2007.02938.x · PMID 17578485 · PMC2203276
36. Journal / agency Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Research. December 1996. doi:10.1016/S0006-8993(96)00968-7 · PMID 9117424
37. Harm reduction site Pramipexole
38. Journal / agency Mirapex (pramipexole dihydrochloride)
39. Journal / agency Highlights of prescribing information
40. Journal / agency Kang X, Wang W, Zuo Y, Wang Y, Zhang L, Liu L. Dopamine receptor agonist pramipexole exerts neuroprotection on global cerebral ischemia/reperfusion injury by inhibiting ferroptosis. Journal of Stroke and Cerebrovascular Diseases. January 2025. doi:10.1016/j.jstrokecerebrovasdis.2024.108101 · PMID 39490461
41. Journal / agency Kang X, Liu L, Wang W, Wang Y. Effects of different doses of dopamine receptor agonist pramipexole on neurobehaviors and changes of mitochondrial membrane potentials in rats with global cerebral ischemia-reperfusion injury. Journal of Stroke and Cerebrovascular Diseases. July 2023. doi:10.1016/j.jstrokecerebrovasdis.2023.107142 · PMID 37105127
42. Journal / agency Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. May 1995. doi:10.1016/0092-8674(95)90072-1 · PMID 7538908
43. Journal / agency Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. May 2008. doi:10.1016/j.cell.2008.03.036 · PMID 18485876
44. Journal / agency Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. December 2008. doi:10.1016/j.cell.2008.12.004 · PMID 19109884
45. Journal / agency Liu C, Sun X, Cai Y, Li D, Li B, Gao R, Zhang L, Chen G. Pramipexole alleviates traumatic brain injury in rats through inhibiting necroptosis. Neuroscience Letters. November 2022. doi:10.1016/j.neulet.2022.136911 · PMID 36243204
46. Journal / agency DeBattista C, Solvason HB, Breen JA, Schatzberg AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. Journal of Clinical Psychopharmacology. April 2000. doi:10.1097/00004714-200004000-00029 · PMID 10770475
47. Journal / agency Zarate CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biological Psychiatry. July 2004. doi:10.1016/j.biopsych.2004.03.013 · PMID 15219473
48. Journal / agency Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. The American Journal of Psychiatry. March 2004. doi:10.1176/appi.ajp.161.3.564 · PMID 14992985
49. Journal / agency Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. European Neuropsychopharmacology. November 2008. doi:10.1016/j.euroneuro.2008.07.005 · PMID 18725178
50. Journal / agency McAllister-Williams H, Chadwick T, Courtney P, Moore A, Fouweather T, Geddes J, Goudie N, Morriss R, Simon J, Smith D, Stokes P. A randomised double-blind, placebo-controlled trial of pramipexole for patients with treatment resistant bipolar depression (the Pramipexole Trial for Bipolar Depression). Neuroscience Applied. 2023-01-01. doi:10.1016/j.nsa.2023.102938
51. Journal / agency Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disorders. October 2002. doi:10.1034/j.1399-5618.2002.01171.x · PMID 12479663
52. Journal / agency Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB. Pramipexole in treatment-resistant depression: an extended follow-up. Depression and Anxiety. 2004. doi:10.1002/da.20038 · PMID 15549689
53. Journal / agency Li P, Wang T, Guo H, Liu Y, Zhao H, Ren T, Tang Y, Wang Y, Zou M. Pramipexole improves depression-like behavior in diabetes mellitus with depression rats by inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing impaired neuroplasticity. Journal of Affective Disorders. July 2024. doi:10.1016/j.jad.2024.04.073 · PMID 38657764
54. Journal / agency Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis and Rheumatism. August 2005. doi:10.1002/art.21191 · PMID 16052595
55. Journal / agency Herceg M, Nagy F, Pál E, Janszky J, Késmárky I, Komoly S, Kovács N. Pramipexole may be an effective treatment option in essential tremor. Clinical Neuropharmacology. March 2012. doi:10.1097/WNF.0b013e31824687bf · PMID 22318193
56. Journal / agency Kosmowska B, Wardas J, Głowacka U, Ananthan S, Ossowska K. Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. CNS Neuroscience & Therapeutics. January 2016. doi:10.1111/cns.12467 · PMID 26459182 · PMC6492867
57. Journal / agency Finkel MF. Pramipexole is a possible effective treatment for primary orthostatic tremor (shaky leg syndrome). Archives of Neurology. October 2000. doi:10.1001/archneur.57.10.1519 · PMID 11030807
58. Journal / agency Lynn BK, Grabenhorst C, Komisaruk BR, Goldstein I, Pfaus J. The Use of Pramipexole to Treat Persistent Genital Arousal Disorder: A Case Report. Sexual Medicine. August 2021. doi:10.1016/j.esxm.2021.100372 · PMID 34126431 · PMC8360918
59. Other Sifrol
60. Other Pipexus 0.52 mg Prolonged-release Tablets - Summary of Product Characteristics (SmPC) - (emc)
61. Other Glepark Tabletten
62. Other Oprymea - 1,05 mg, tabletki o przedłużonym uwalnianiu
63. Other Pramipexole (International database)

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.